When should a biotech company bring in external CMC expertise?
- Mar 27
- 5 min read
For many biotech companies, the early stages of development are dominated by scientific discovery and proof of concept. Once promising data begins to emerge, attention quickly shifts to the next challenge: how to translate a promising molecule into a manufacturable, scalable and regulatory-ready product.
This is where Chemistry, Manufacturing and Controls (CMC) becomes critical. As discussed in our article on developing a robust CMC strategy early in biotech development, decisions made during early development shape everything that follows, from manufacturing strategy and timelines to regulatory submissions and ultimately commercial success.
As programmes progress towards key development milestones, the question often arises: when is the right time to bring in external CMC expertise?
The answer depends on several factors, but there are clear points during development when strategic CMC support for biotech companies can make a significant difference.
Bringing in CMC expertise at the right stage helps ensure that early technical decisions are made with the full development pathway in mind.
Why early CMC decisions shape development timelines
CMC strategy is sometimes viewed as an operational task that can be addressed later in development. In reality, it should evolve alongside the scientific programme, as early decisions influence several aspects of development, including:
selection of the appropriate manufacturing platform
development of robust and scalable processes
alignment with regulatory expectations
the ability to transition smoothly from research to clinical manufacturing
These decisions should be guided by a well-defined Target Product Profile (TPP), which describes the intended clinical and commercial characteristics of the product.
If these aspects are not considered early enough, programmes can encounter delays when moving towards IND-enabling studies or first-in-human trials. Manufacturing processes may require re-engineering, analytical methods may not meet regulatory expectations, or the selected manufacturing partner may not be suitable for later development stages.
For emerging biotech companies operating under funding and timeline pressures, these setbacks can have significant consequences.
Warning signs a company may need external CMC expertise
Many biotech teams recognise the importance of CMC but may underestimate the complexity involved. Several common situations signal that external expertise could add value.
One of the most common indicators is limited internal CMC leadership. Start-ups often have exceptional scientific teams but may not yet have senior professionals with experience in process development, manufacturing strategy or regulatory CMC requirements.
Another sign is uncertainty around manufacturing strategy. Questions such as which expression system to use, how to approach scale-up, or which CDMO capabilities are required can have long-term implications. Without experience across multiple development programmes, these decisions can be difficult to navigate.
Companies may also struggle with coordinating multiple development activities, particularly when working with external partners. Managing CDMOs, analytical development and regulatory preparation simultaneously requires structured oversight.
Finally, approaching key development milestones often exposes gaps in internal capabilities. Conducting early risk assessment in drug development can help identify these challenges before they affect timelines. Preparing for clinical manufacturing or regulatory submissions typically requires a level of CMC coordination that many early teams have not yet built internally.
External advisors can provide the strategic oversight needed to navigate these stages with confidence.
Key inflection points in biotech development
While every programme is different, there are several moments during development when external CMC expertise becomes particularly valuable.
Preparing for IND-enabling development
As a programme progresses towards clinical development, manufacturing and analytical strategies must align with regulatory expectations. This stage often involves defining the development pathway, establishing process development plans and ensuring analytical methods will support future submissions.
Experienced CMC advisors can help shape these plans before critical work begins.
Selecting and managing a CDMO
Choosing the right manufacturing partner is one of the most consequential decisions for a biotech company, particularly when selecting and managing CDMO partnerships. The capabilities, technology platforms and regulatory track record of a CDMO can influence both development timelines and long-term manufacturing strategy.
External experts with experience across multiple CDMO partnerships can help evaluate potential partners and support technical due diligence.
Transitioning from research to GMP manufacturing
Moving from laboratory research to GMP manufacturing introduces new regulatory, quality and operational requirements. Process robustness, documentation and analytical validation all become increasingly important.
External support at this stage can help ensure that processes developed in research environments translate successfully into GMP production.
Scaling up manufacturing
As programmes advance through clinical development, manufacturing processes must be scaled to meet increasing demand. Scaling up without compromising product quality or consistency requires careful technical planning and oversight.
External specialists can help anticipate potential challenges before they become critical obstacles.
What experienced CMC advisors actually do
External CMC advisors do more than provide occasional technical input. In many cases, they act as strategic partners who help shape and guide the overall development pathway.
Their role often includes activities such as:
reviewing and refining CMC development strategies
supporting the definition of Target Product Profiles and quality targets
evaluating manufacturing platforms and technology choices
supporting CDMO selection and technical due diligence
overseeing process development and manufacturing activities
coordinating analytical development and documentation
contributing to regulatory submission preparation
The role of CMC consultants in biotech development
For early-stage biotech companies, bringing in external expertise often means working with experienced CMC consultants who have supported multiple development programmes across different modalities and regulatory environments.
CMC consultants, like 3Biotech, typically provide independent technical leadership during key stages of development. Their role is not simply advisory; they often act as an extension of the internal team, helping coordinate complex development activities and ensuring technical decisions remain aligned with long-term regulatory and manufacturing goals.
In practice, this support may include reviewing development strategies, guiding manufacturing planning, supporting CDMO selection, and overseeing process and analytical development activities. Experienced consultants can also help prepare the CMC sections of regulatory submissions and ensure that documentation meets regulatory expectations.
For companies without a large internal CMC organisation, this model provides access to senior expertise when it is most needed, without requiring immediate internal expansion.
Because experienced advisors have worked across multiple development programmes, they can often identify risks or inefficiencies that may not be immediately visible to internal teams.
Their perspective can help ensure that development activities remain aligned with long-term regulatory and commercial goals.
Examples of how this support works in practice can be seen in our resources.
How the right support accelerates development and reduces risk
Biotech companies operate in an environment where time and capital are closely linked.
Delays in development can affect investor confidence, funding timelines and competitive positioning.
Experienced CMC leadership helps teams make development decisions with a clear understanding of the full product lifecycle.
Early external support can help companies:
avoid costly manufacturing redesigns later in development
select CDMO partners that match both current and future needs
ensure regulatory expectations are considered from the outset
maintain development momentum as programmes progress
Rather than replacing internal expertise, external advisors typically work alongside biotech teams, providing targeted leadership where it is most needed.
For early-stage companies building internal capabilities, this approach provides access to senior CMC expertise without the need to immediately expand the organisation.
Strategic CMC support for growing biotech companies
Every biotech programme faces different technical challenges, but one principle remains consistent: the earlier CMC strategy is integrated into development planning, the smoother the path to clinical and commercial success is likely to be.
External expertise can provide valuable perspective at key stages of development, helping companies navigate complex technical decisions while maintaining development momentum.
If your programme is approaching key development milestones, our team can help assess your CMC strategy and identify potential risks before they affect timelines.
Learn more about how 3Biotech supports biotech companies through our CMC advisory services.
